Azizul Haque, Ph.D.
Studies in Dr. Haque's laboratory are probing the factors responsible for immune evasion by G-cell lymphomas. While MHC class I-restricted CD8+ T cells are effector cells in anti-tumor immune responses, MHC class II-restricted CD4+ T cells can play critical roles in initiating, regulating, and maintaining anti-tumor immune responses. Since most B-cell tumors express MHC class II molecules, these tumors can be potential target for CD4+ T cells.
Research Interest
Dr. Haque's laboratory conducts research in the areas of cancer immunology, inflammation, and neurodegeneration. In cancer immunology, we are investigating the mechanisms by which malignant tumors such as lymphoma, prostate and melanoma evade immune recognition via MHC class I and II pathways. Elucidating the mechanisms of loss of immune recognition in the context of MHC molecules will contribute to the development of effective immunotherapeutic(s) against malignant diseases.